Author

S. M. Scheaffer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:drug response / drug discovery· 5 Research Focus:host-pathogen & immune response· 5 Organism:mouse· 5 Assay:proteomics· 3 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

M. S. Diamond· 7 shared B. Whitener· 4 shared B. Ying· 4 shared L. B. Thackray· 4 shared A. Carfi· 3 shared D. K. Edwards· 3 shared D. Lee· 3 shared J. B. Case· 3 shared

Activity by Year

2021-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersMicrobiology

M. S. Diamond

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron Variants in Mice and Hamsters

J. B. Case, S. M. Scheaffer, T. L. Darling, T. L. Bricker, L. J. Adams, H. H. Harastani, R. Trende, S. Sanapala, D. H. Fremont, A. C. M. Boon, M. S. Diamond

This paper evaluates the pathogenicity of SARS-CoV-2 BQ.1.1 and BA.5.5 variants in multiple rodent models, finding increased virulence in transgenic mice but not in conventional mice or hamsters.

bioRxiv · Apr 28, 2023 · PreprintMicrobiology

Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants

T. A. Desautels, K. T. Arrildt, A. T. Zemla, E. Y. Lau, F. Zhu, D. Ricci, S. Cronin, S. Zost, E. Binshtein, S. M. Scheaffer, B. Dadonaite, B. K. Petersen, T. B. Engdahl, E. Chen, L. S. Handal, , Carnahan

This paper computationally redesigns an antibody to restore potency against SARS-CoV-2 Omicron subvariants while maintaining efficacy against Delta and other variants.

bioRxiv · Oct 21, 2022Microbiology

Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domains

G. Stewart-Jones, S. M. Elbashir, K. Wu, D. Lee, I. Renzi, B. Ying, M. Koch, C. E. Sein, A. Choi, B. Whitener, D. Garcia-Dominguez, C. Henry, A. Woods, L. Ma, D. Montes Berrueta, , A. Carfi

The paper develops and evaluates an mRNA vaccine, mRNA-1283, encoding SARS-CoV-2 spike N-terminal and receptor-binding domains, showing improved immunogenicity and protection against multiple variants in mice.

bioRxiv · Oct 7, 2022 · PreprintImmunology

SARS-CoV-2 Omicron boosting induces de novo B cell response in humans

W. B. Alsoussi, S. K. Malladi, J. Q. Zhou, Z. Liu, B. Ying, W. Kim, A. J. Schmitz, T. Lei, S. C. Horvath, A. J. Sturtz, K. M. McIntire, B. Evavold, F. Han, S. M. Scheaffer, I. F. Fox, , A. H. Ellebedy

This study shows that SARS-CoV-2 boosting induces GC B cell responses and that Omicron-based vaccines can elicit novel epitope-specific antibodies despite antigenic imprinting.

bioRxiv · Sep 22, 2022Immunology

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant

S. M. Scheaffer, D. Lee, B. Whitener, B. Ying, K. Wu, H. Jani, P. Martin, N. J. Amato, L. E. Avena, D. M. Berrueta, S. D. Schmidt, S. O'Dell, A. Nasir, G.-Y. Chuang, G. Stewart-Jones, , M. S. Diamond

This study evaluates bivalent SARS-CoV-2 mRNA vaccines and finds they induce broader neutralizing antibodies and better protection against BA.5 Omicron compared to monovalent vaccines.

bioRxiv · Sep 12, 2022 · PreprintMicrobiology

Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice

B. Ying, S. M. Scheaffer, B. Whitener, C.-Y. Liang, O. Dmytrenko, S. Mackin, K. Wu, D. Lee, L. E. Avena, Z. Chong, J. B. Case, L. Ma, T. Kim, C. Sein, A. Woods, , M. S. Diamond

This study shows that boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibodies and protection against B.1.1.529 in mice, with the Omicron-matched booster showing slightly better outcomes.

bioRxiv · Feb 7, 2022 · PreprintMicrobiology

Preclinical Efficacy of IMM-BCP-01, a Highly Active Patient-Derived Anti-SARS-CoV-2 Antibody Cocktail

P. A. Nikitin, J. M. DiMuzio, J. P. Dowling, N. B. Patel, J. L. Bingaman-Steele, C. Nicolescu, B. C. Heimbach, N. Henriquez, E. L. Sikorsky, A. Polley, R. J. Howanski, M. Nath, H. Shukla, S. M. Scheaffer, J. P. Finn, , M. K. Robinson

The paper identifies and characterizes an antibody cocktail, IMM-BCP-01, that neutralizes SARS-CoV-2 variants in vitro and inhibits infection in vivo through Spike Trimer dissociation and effector responses.

bioRxiv · Oct 18, 2021 · PreprintImmunology